SEC Form 4 · accession 0000029905-18-000006
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 5, 2018
Accepted (ET)
Jan 30, 2018 · 2:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jan 5, 2018 | P | 527,472 | $22.75 | A | 5,632,802 | I | By subsidiary |
| Common SharesF2 | holding | — | — | — | 75,945 | I | By subsidiary |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner.
- F2Reflects shares of CRISR received by a subsidiary of Bayer AG as a pro rata distribution from a limited partnership. Bayer AG is the 100% Indirect Owner through subsidiaries of such shares.